Health Care/Hospital

ANEW MEDICAL, INC. Enters Into Definitive Merger Agreement with Redwoods Acquisition Corp.

* ANEW MEDICAL, INC. ("ANEW") has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ: RWOD). * ANEW is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurogenerative diseases. * ANEW ...

2023-05-30 18:00 3035

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Prophage and Jamphage are expected to play a substantial role in bacterial survival and immune regulation in the body. BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ...

2023-05-30 10:15 1838

Bridge Biotherapeutics to Present at the 2023 BIO International Convention

SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation onTuesday, June...

2023-05-30 06:00 2268

CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held

SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou. The...

2023-05-29 20:03 3228

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...

2023-05-29 16:51 2952

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating ant...

2023-05-29 13:21 2240

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...

2023-05-29 09:42 2236

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...

2023-05-28 21:00 3006

Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system

SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation.  Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosi...

2023-05-26 22:08 3963

E-Home Household Services Holdings Limited Announces Half-Year Results Ended December 31, 2022

FUZHOU, China, May 26, 2023 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced its financial results for the six months endedDecember 31, 2022. Financial Highlight * Total re...

2023-05-26 21:06 5460

ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic

* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...

2023-05-26 20:00 2338

Waterdrop Inc. to Report First Quarter 2023 Financial Results on June 5, 2023

BEIJING, May 26, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform de...

2023-05-26 19:30 4352

FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health

Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...

2023-05-26 13:42 2255

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference

SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...

2023-05-26 10:01 3184

Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting

SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting,June 2-6, 2023 in Chicago. The data which include updated analyses of Dizal's two leading assets...

2023-05-26 06:00 2213

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...

2023-05-26 06:00 2357

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation ofpatients' immune system against cancer cells. -  In newly diagnosed patients who were not eligible for or declined chemotherapy treatment, 63% of the patients with CD73High and PD-L1 T...

2023-05-26 05:01 2303

Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting

- New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global leader of AI-powered cancer diagnostics and therapeutics soluti...

2023-05-26 05:00 2229

TORRAS launches innovative new wearable air conditioner, COOLIFY 3

NEW YORK, May 25, 2023 /PRNewswire/ -- COOLIFY has revolutionized portable cooling devices with the introduction of COOLIFY 3, the latest innovation in wearable air conditioners. Designed to provide a cool and comfortable experience, even in scorching temperatures, COOLIFY 3 incorporates cutting-...

2023-05-25 22:58 2562

Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023

SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today announced that Hepagene will present two posters highlighting the preclinical and clinical developm...

2023-05-25 22:00 2033
1 ... 949596979899100 ... 277

Week's Top Stories